How to Buy Entrada Therapeutics Stock
Entrada Therapeutics Inc
Entrada Therapeutics, Inc. , a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
Entrada Therapeutics stock last closed at $9.90, down 2.7% from the previous day, and has decreased 28.05% in one year. It has overperformed other stocks in the Biotechnology industry by 0.53 percentage points. Entrada Therapeutics stock is currently +1.59% from its 52-week low of $9.75, and -54.57% from its 52-week high of $21.79.
There are currently 37.59M TRDA shares outstanding. The market cap of TRDA is $372.19M. In the last 24 hours, 85,571 TRDA shares were traded.
How to Buy Entrada Therapeutics Stock
Wondering how to invest in Entrada Therapeutics stock? Here's how.
- Figure out where to buy Entrada Therapeutics stock: You need to choose an online brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you decide where to buy Entrada Therapeutics stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Pick your payment method and add your info.
- Analyze Entrada Therapeutics stock: The Entrada Therapeutics ticker symbol is TRDA. Is Entrada Therapeutics stock a good investment? Should you buy shares of TRDA? How do TRDA's underlying business fundamentals look? Do top analysts think Entrada Therapeutics is a good buy? Why has TRDA's stock price moved recently? (Hint: Our stock market research website can help you evaluate if TRDA is a good stock to buy).
- Execute your TRDA purchase: Decide if you will purchase TRDA shares at the current market price or use a limit order to purchase TRDA stock at a given price.
- Keep tabs on your TRDA investment: Create a watchlist to keep track of your investment in Entrada Therapeutics stock.
Step 1: Figure out where to buy Entrada Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy TRDA stock.
Our recommended brokerage: eToro
Based on our research, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the best brokerage, you'll need to fill out some personal information so you are able to buy TRDA stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to create a new brokerage account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've opened your account on one of the most highly reviewed stock apps, you can securely and quickly fund your account:
Watch the tutorial below for more details transferring funds into your investment account.
Step 4: Analyze Entrada Therapeutics stock
After you have selected the best place to buy Entrada Therapeutics stock, it's absolutely critical to analyze their stock prior to buying, so you truly comprehend the risk as well as the opportunity.
Entrada Therapeutics shares quick numbers
Entrada Therapeutics Due Diligence Score
WallStreetZen was built to help everyday investors perform better fundamental analysis in less time.
You can view all of the due diligence checks on TRDA's stock page.
How is TRDA stock valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge TRDA's true value.
Using relative valuations metrics:
- TRDA may be undervalued based on its P/E ratio of 5.63x, relative to Biotechnology industry P/E ratio of -115.59x
- TRDA may be undervalued based on its P/B ratio of 0.87x, relative to Biotechnology industry P/B ratio of 4.53x
You can access more valuation research on TRDA's stock here.
How do TRDA Financials look?
Signs that TRDA is financially healthy:
- There are more short-term assets than short-term liabilities on the TRDA balance sheet.
- TRDA has $423.95M in cash and short term investments. This is sufficient to cover its annual cash burn of $44.72M.
- TRDA has cash burn of 44715000. It has sufficient cash and short-term investments to cover this for at least one year.
- Total TRDA debt is lower than 5 years ago, relative to shareholder equity.
- TRDA has a low debt to equity ratio of 0.23.
- There are more short-term assets than long-term liabilities on the TRDA balance sheet.
- TRDA profit margin has gone up from -5.2% to 31.1% in the past year.
Is TRDA stock a Buy, Hold, or Sell, according to analysts?
Out of 3 Equities analysts who monitor TRDA, the consensus analyst rating on Entrada Therapeutics is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are saying on the Entrada Therapeutics stock forecast page.
TRDA Trading Indicators
How is TRDA performing as a company?
Last year, TRDA revenue was $210.78M. Over the past 1 years, TRDA's revenue has grown by 63.38% per year. This was faster than the Biotechnology industry average of 46.16%.
Find out more about TRDA's earnings and revenue performance here.
Latest Insiders Trades at TRDA
In the past year, executives and large shareholders at TRDA have sold more shares than they have bought.
Kory James Wentworth, Chief Financial Officer of TRDA, was the latest TRDA insider to sell. They sold $19,035.28 worth of TRDA shares on Mar 17, 2025.
Dig into more about who owns TRDA shares here.
Can I get consistent income from TRDA stock?
No, Entrada Therapeutics doesn't provide an income stream by paying out dividends.
TRDA Social Trading Data
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your TRDA purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally fine for most investors. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given price, use a limit order.
Hit the Open Trade button and your broker will execute the order.
If you need more info about buying stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your TRDA investment
Now that you own some shares in TRDA, you'll want to keep up with your new company.
Make a watchlist to keep tabs on your TRDA stock.
TRDA Feed
How to Buy Stock in Entrada Therapeutics
To reiterate, here are the 6 steps to buy Entrada Therapeutics stock:
- Figure out where to buy Entrada Therapeutics stock
- Open a brokerage account
- Deposit funds into your investment account
- Analyze Entrada Therapeutics stock
- Execute your TRDA purchase
- Keep tabs on your TRDA investment
If you require a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to track your new investment in Entrada Therapeutics, get started below.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.